2,6-dihydroxy-3-cyanopyridine: inhibitor of 5-fluorouracil degradation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 100608 |
| CHEMBL ID | 3086508 |
| SCHEMBL ID | 1048225 |
| SCHEMBL ID | 9614840 |
| MeSH ID | M0150756 |
| Synonym |
|---|
| nsc329880 |
| 35441-10-2 |
| nsc-329880 |
| 2-hydroxy-6-oxo-1h-pyridine-3-carbonitrile |
| 2,6-dihydroxynicotinonitrile |
| 6-hydroxy-2-oxo-1,2-dihydropyridine-3-carbonitrile |
| A18682 |
| 1,2-dihydro-6-hydroxy-2-oxo-3-pyridinecarbonitrile |
| nsc 329880 |
| 2,6-dihydroxy-3-cyanopyridine |
| 2,6-cndp |
| 3-cyano-2,6-dihydroxypyridine |
| 3-pyridinecarbonitrile, 1,2-dihydro-6-hydroxy-2-oxo- |
| AKOS006338491 |
| CHEMBL3086508 , |
| bdbm50443015 |
| SCHEMBL1048225 |
| BFHKYHMCIAMQIN-UHFFFAOYSA-N |
| 3-cyano-6-hydroxy-pyridin-2-ol |
| SCHEMBL9614840 |
| Q-101510 |
| mfcd11558977 |
| DTXSID90188927 |
| CS-W005677 |
| 2,6-dihydroxypyridine-3-carbonitrile |
| AS-59743 |
| 3-cyano-6-hydroxy-2(1h)-pyridinone |
| FT-0737473 |
| 2-hydroxy-6-oxo-1,6-dihydropyridine-3-carbonitrile |
| BCP34567 |
| 2,6-dihydroxy-3-cyanopyridine;3-cyano-2,6-dihydroxypyridine |
| SY047890 |
| mfcd11113421 |
| 3-pyridinecarbonitrile, 1,2,5,6-tetrahydro-2,6-dioxo- |
| 71350-42-0 |
| 1,2,5,6-tetrahydro-2,6-dioxo-3-pyridinecarbonitrile |
| nicotinonitrile, 2,6-dihydroxy- |
| 5WDJ8G2R9N |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Methods for pharmacokinetic modulation of the plasma 5-fluorouracil (5-FU) level to increase antitumor activity during continuous venous infusion (CVI) of low doses of 5-FU were examined in Yoshida sarcoma-bearing rats." | ( Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil. Fujii, S; Fukushima, M; Shimamoto, Y; Shirasaka, T, 1989) | 0.28 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Thymidine phosphorylase | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0200 | 1.5838 | 6.8000 | AID1054088 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Uridine phosphorylase 1 | Homo sapiens (human) | Kd | 1.0450 | 0.0200 | 1.4995 | 6.6000 | AID1054084; AID1054085; AID1054087 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Uridine phosphorylase 1 | Homo sapiens (human) | Kii | 1.6060 | 0.1300 | 0.7710 | 2.5460 | AID1054090; AID1054093 |
| Uridine phosphorylase 1 | Homo sapiens (human) | Kis | 1.5875 | 0.3750 | 1.0242 | 2.6100 | AID1054091; AID1054098 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| 1,4-alpha-oligoglucan phosphorylase activity | Thymidine phosphorylase | Homo sapiens (human) |
| protein binding | Thymidine phosphorylase | Homo sapiens (human) |
| growth factor activity | Thymidine phosphorylase | Homo sapiens (human) |
| thymidine phosphorylase activity | Thymidine phosphorylase | Homo sapiens (human) |
| protein homodimerization activity | Thymidine phosphorylase | Homo sapiens (human) |
| uridine phosphorylase activity | Uridine phosphorylase 1 | Homo sapiens (human) |
| thymidine phosphorylase activity | Uridine phosphorylase 1 | Homo sapiens (human) |
| identical protein binding | Uridine phosphorylase 1 | Homo sapiens (human) |
| deoxyuridine phosphorylase activity | Uridine phosphorylase 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Thymidine phosphorylase | Homo sapiens (human) |
| cytosol | Thymidine phosphorylase | Homo sapiens (human) |
| nucleoplasm | Uridine phosphorylase 1 | Homo sapiens (human) |
| cytosol | Uridine phosphorylase 1 | Homo sapiens (human) |
| cytosol | Uridine phosphorylase 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1054095 | Time dependent inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using URD and inorganic phosphate as substrate at 1 uM by spectrophotometric analysis | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity. |
| AID1054087 | Binding affinity to human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) by isothermal titration calorimetric analysis | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity. |
| AID1054084 | Binding affinity to human recombinant UP1-R1P binary complex expressed in Escherichia coli Rosetta (DE3) at 150 uM R1P by isothermal titration calorimetric analysis | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity. |
| AID1054091 | Non-competitive inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using inorganic phosphate as substrate assessed as equilibrium dissociation constant for enzyme-inhibitor complex by Lineweaver-Burk plot analysis | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity. |
| AID1054088 | Inhibition of human thymidine phosphorylase | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity. |
| AID1054096 | Inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using URD and inorganic phosphate as substrate at 1 uM after 60 seconds by spectrophotometric analysis relative to control | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity. |
| AID1054093 | Non-competitive inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using URD as substrate assessed as equilibrium dissociation constant for enzyme-substrate-inhibitor complex by Lineweaver-Burk plot analysis | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity. |
| AID1054098 | Non-competitive inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using URD as substrate assessed as equilibrium dissociation constant for enzyme-inhibitor complex by Lineweaver-Burk plot analysis | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity. |
| AID1054090 | Non-competitive inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using inorganic phosphate as substrate assessed as equilibrium dissociation constant for enzyme-substrate-inhibitor complex by Lineweaver-Burk plot analysis | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity. |
| AID1054085 | Binding affinity to human recombinant UP1-R1P binary complex expressed in Escherichia coli Rosetta (DE3) at 50 uM R1P by isothermal titration calorimetric analysis | 2013 | Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21 | Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.02) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||